Business
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in ApoE4 carriersPhase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company dev
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V2aX3COZJf3aT17udXAGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Buntanetap improved cognition in pTau217-positive early AD patients","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Buntanetap was safe and well-tolerated, including in ApoE4 carriers","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":339,"olType":false},{"type":"text","content":"MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a new publication titled “Buntanetap treatment in mild to moderate Alzheimer’s disease: phase 2/3 study” in a peer-reviewed journal Nature NPJ Dementia.","length":484,"tagName":"p"},{"type":"text","content":"The Phase 2/3 study (NCT05686044) was a randomized, double-blinded, placebo-controlled trial evaluating three doses of buntanetap (7.5 mg, 15 mg, and 30 mg) over 12 weeks in 351 patients with mild to moderate AD. The study demonstrated that buntanetap was safe and well-tolerated across all disease stages and dose levels. Notably, safety was also assessed in ApoE4 carriers, the most genetically at-risk population for AD, with no increase in adverse events compared to non-carriers and to placebo. Given buntanetap's distinct mechanism of action, the drug was also well-tolerated when taken alongside approved symptoma...